Results 91 to 100 of about 24,893 (251)

Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology

Brazilian Journal of Nephrology, 2018
Scleroderma is an autoimmune disease that affects multiple systems. While pathophysiologic mechanisms governing the development of scleroderma are relatively poorly understood, advances in our understanding of the complement system are clarifying the ...
Roman Zuckerman, Arif Asif, Eric J. Costanzo, Tushar Vachharajani   +3 more
doaj   +1 more source

Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]

, 2015
Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael, Parikh, MD, Kinjal   +1 more
core   +2 more sources

Common Hematologic Emergencies—Acute Promyelocytic Leukemia and Microangiopathic Hemolytic Anemias—A Pivotal Role of Clinical Laboratory

International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 521-530, June 2026.
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova, Nicolas Ulrich Edgar, Anton V. Rets   +2 more
wiley   +1 more source

Typical and Atypical Hemolytic Uremic Syndrome

Kidney and Blood Pressure Research, 1996
The hemolytic uremic syndrome is the most frequent cause of acute renal failure in childhood. In the vast majority of patients, the syndrome of acute hemolysis, thrombopenia and renal dysfunction is preceded by an episode of diarrhea with or without bloody stools.
openaire   +2 more sources

The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.

Kidney International, 2020
Ravulizumab, a long-acting complement C5 inhibitor engineered from eculizumab, allows extending maintenance dosing from every 2-3 weeks to every 4-8 weeks depending on bodyweight.
G. Ariceta, B. Dixon, Seong Heon Kim, G. Kapur, Teri J Mauch, S. Ortiz, M. Vallée, A. Denker, H. Kang, L. Greenbaum, H. Lovell, Melissa Muff-Luett, Kristin Malone, Oluwasegun Adeagbo, Alexandria Wilkerson, G. Fraga, Scherezade Sarri, H. Cheong, Y. Ahn, K. Han   +19 more
semanticscholar   +1 more source

Severe SARS-COV-2 infection in pediatric patient with atypical Hemolytic Uremic Syndrome: A case report

Annals of Medicine and Surgery, 2022
Introduction and important There is a high incidence of acute kidney injury with COVID-19 infections. We report a child with atypical Hemolytic Uremic Syndrome (aHUS) admitted to Intensive care Unit (ICU) due to severe SARS-COV-2 infection.
S. Hamza
semanticscholar   +1 more source

MULTIFACTORIAL ETIOLOGY OF ATIPICAL HEMOLYTIC UREMIC SYNDROME-CASE REPORT [PDF]

Sanamed
Introduction: Hemolytic uremic syndromes are characterized by the simultaneous occurrence of hemolytic anemia, microangiopathy, thrombocytopenia, and acute renal insufficiency.
Skoric Jasmina, Klacar Uzelac Marija, Kostic Ana   +2 more
doaj   +1 more source

Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizimab treatment [PDF]

, 2016
Background: Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS). Guidelines discuss the importance of prompt treatment. We report a post hoc analysis investigating the effect of baseline factors, including patient characteristics and ...
Ardissimo, Gianluigi, Delmas, Yahsou, Haller, Herman, Kincaid, John F, Vande Walle, Johan, Wang, Jimmy   +5 more
core   +2 more sources

Reversible cerebral vasoconstriction syndrome: A narrative review

Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1162-1180, May 2026.
Abstract Objectives/Background This review summarizes current insights into Reversible cerebral vasoconstriction syndrome (RCVS) diagnosis, management, and outcomes. RCVS is a cerebrovascular disorder characterized by recurrent thunderclap headaches and transient segmental vasoconstriction of cerebral arteries, typically resolving within 3 months ...
Ícaro Araújo de Sousa, Abner da Silva Machado, Arthur de Oliveira Veras, Thiago Oscar Goulart, Sarah Galassi Tatsuta, Trajano Aguiar Pires Gonçalves, Eva Rocha, Octávio Marques Pontes‐Neto   +7 more
wiley   +1 more source

Primary Thrombotic Microangiopathy in Pediatric Patients

Global Pediatric Health
Background . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology .
Andrés David Aranzazu Ceballos MD, Lina María Martínez Sánchez MSc, Ana Paulina Pamplona Sierra MD, Daniela Vergara Yánez MD, Liliana Franco Hincapié PhD, Richard Baquero Rodriguez MD   +5 more
doaj   +1 more source